| Are cardiovascular risk factors also associated with the incidence of atrial fibrillation? V Allan, S Honarbakhsh, JP Casas, J Wallace, R Hunter, R Schilling, ... Thrombosis and haemostasis 117 (05), 837-850, 2017 | 186 | 2017 |
| Trends in hospital treatments, including revascularisation, following acute myocardial infarction, 2003–2010: a multilevel and relative survival analysis for the National … CP Gale, V Allan, BA Cattle, AS Hall, RM West, A Timmis, HH Gray, ... Heart 100 (7), 582-589, 2014 | 140 | 2014 |
| Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants V Allan, SV Ramagopalan, J Mardekian, A Jenkins, X Li, X Pan, X Luo Journal of comparative effectiveness research 9 (9), 603-614, 2020 | 125 | 2020 |
| Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care V Allan, A Banerjee, AD Shah, R Patel, S Denaxas, JP Casas, ... Heart 103 (3), 210-218, 2017 | 61 | 2017 |
| Age-dependent improvements in survival after hospitalisation with acute myocardial infarction: an analysis of the Myocardial Ischemia National Audit Project (MINAP) OA Alabas, V Allan, JM McLenachan, R Feltbower, CP Gale Age and ageing 43 (6), 779-785, 2014 | 59 | 2014 |
| Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study F Barlesi, A Dixmier, D Debieuvre, C Raspaud, JB Auliac, N Benoit, ... Oncoimmunology 9 (1), 1744898, 2020 | 32 | 2020 |
| Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis A Banerjee, V Allan, S Denaxas, A Shah, D Kotecha, PD Lambiase, ... EP Europace 21 (12), 1776-1784, 2019 | 28 | 2019 |
| Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada D Debieuvre, RA Juergens, B Asselain, C Audigier-Valette, JB Auliac, ... Lung Cancer 157, 40-47, 2021 | 20 | 2021 |
| Bleeding in cardiac patients prescribed antithrombotic drugs: electronic health record phenotyping algorithms, incidence, trends and prognosis L Pasea, SC Chung, M Pujades-Rodriguez, AD Shah, S Alvarez-Madrazo, ... BMC medicine 17, 1-14, 2019 | 17 | 2019 |
| Factors associated with non-prescription of oral anticoagulant treatment in non-valvular atrial fibrillation patients with dementia: a CPRD–HES study M Besford, S Graham, C Sammon, F Mehmud, V Allan, R Alikhan, ... Age and Ageing 49 (4), 679-682, 2020 | 14 | 2020 |
| Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian … S Ramagopalan, V Allan, S Saragoni, LD Esposti, D Alessandrini, ... Journal of Comparative Effectiveness Research 7 (11), 1063-1071, 2018 | 5 | 2018 |
| IO-synthesise NSCLC: A pooled analysis of real-world survival outcomes for non-small cell lung cancer patients treated with nivolumab in France and Germany B Asselain, F Barlesi, D Debieuvre, CA Valette, A Gröschel, S Gütz, ... Annals of Oncology 30, v614, 2019 | 4 | 2019 |
| Impact of atrial fibrillation awareness campaigns: interrupted time series using the Clinical Practice Research Datalink V Allan, CJ Sammon, L McDonald, F Mehmud, R Alikhan, ... Future Cardiology 15 (04), 311-318, 2019 | 3 | 2019 |
| Health-related quality of life (HRQoL) of non-small cell lung cancer (NSCLC) patients treated with nivolumab in real-life: the EVIDENS study M Perol, A Dixmier, F Barlesi, D Debieuvre, C Raspaud, JB Auliac, ... Annals of Oncology 30, ii48, 2019 | 3 | 2019 |
| Prospective, Noninterventional Study of Nivolumab in Real-world Patients With Locally Advanced or Metastatic Non–small Cell Lung Cancer After Prior Chemotherapy (ENLARGE-Lung) M Sebastian, A Gröschel, S Gütz, H Schulz, H Müller-Huesmann, ... Journal of Immunotherapy 45 (2), 89-99, 2022 | 1 | 2022 |
| 1325P Long-term survival and health-related quality of life in patients treated with nivolumab for advanced non-small cell lung cancer: A wide prospective French real-world … F Barlesi, A Dixmier, D Debieuvre, C Raspaud, JB Auliac, N Benoit, ... Annals of Oncology 31, S854-S855, 2020 | 1 | 2020 |
| Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: Updated survival and subgroup analysis from the real-world EVIDENS study F Barlesi, A Dixmier, D Debieuvre, C Raspaud, JB Auliac, N Benoit, ... Annals of Oncology 30, v613, 2019 | 1 | 2019 |
| PCN6 REAL WORLD EFFECTIVENESS OF NIVOLUMAB IN ASIAN PATIENTS IN THE UNITED STATES FLATIRON HEALTH DATABASE V Allan, A Mungul, J Diaz, T Luo, A Harish, S Ramagopalan, J Chang Value in Health 22, S57, 2019 | 1 | 2019 |
| IO-Synthesise RCC: Real-world outcomes with nivolumab in previously treated advanced renal cell carcinoma, a pooled analysis of patients from France and Germany MO Grimm, A Thiery-Vuillemin, J Bedke, V Grünwald, ... European Urology Open Science 33, S319-S320, 2021 | | 2021 |
| 1348P Long-term survival and health-related quality of life with nivolumab for previously-treated advanced non-small cell lung cancer (NSCLC): A wide prospective French real … F Barlesi, A Dixmier, D Debieuvre, C Raspaud, JB Auliac, B Nicolas, ... Annals of Oncology 32, S1026, 2021 | | 2021 |
